A citation-based method for searching scientific literature

Courtney D DiNardo, Eytan M Stein, Stéphane de Botton, Gail J Roboz, Jessica K Altman, Alice S Mims, Ronan Swords, Robert H Collins, Gabriel N Mannis, Daniel A Pollyea, Will Donnellan, Amir T Fathi, Arnaud Pigneux, Harry P Erba, Gabrielle T Prince, Anthony S Stein, Geoffrey L Uy, James M Foran, Elie Traer, Robert K Stuart, Martha L Arellano, James L Slack, Mikkael A Sekeres, Christophe Willekens, Sung Choe, Hongfang Wang, Vickie Zhang, Katharine E Yen, Stephanie M Kapsalis, Hua Yang, David Dai, Bin Fan, Meredith Goldwasser, Hua Liu, Sam Agresta, Bin Wu, Eyal C Attar, Martin S Tallman, Richard M Stone, Hagop M Kantarjian. N Engl J Med 2018
Times Cited: 556







List of co-cited articles
829 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.
Eytan M Stein, Courtney D DiNardo, Daniel A Pollyea, Amir T Fathi, Gail J Roboz, Jessica K Altman, Richard M Stone, Daniel J DeAngelo, Ross L Levine, Ian W Flinn,[...]. Blood 2017
672
71

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
Richard M Stone, Sumithra J Mandrekar, Ben L Sanford, Kristina Laumann, Susan Geyer, Clara D Bloomfield, Christian Thiede, Thomas W Prior, Konstanze Döhner, Guido Marcucci,[...]. N Engl J Med 2017
876
35

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.
Alexander E Perl, Giovanni Martinelli, Jorge E Cortes, Andreas Neubauer, Ellin Berman, Stefania Paolini, Pau Montesinos, Maria R Baer, Richard A Larson, Celalettin Ustun,[...]. N Engl J Med 2019
288
31

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
Hartmut Döhner, Elihu Estey, David Grimwade, Sergio Amadori, Frederick R Appelbaum, Thomas Büchner, Hervé Dombret, Benjamin L Ebert, Pierre Fenaux, Richard A Larson,[...]. Blood 2017
29

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
Courtney D DiNardo, Brian A Jonas, Vinod Pullarkat, Michael J Thirman, Jacqueline S Garcia, Andrew H Wei, Marina Konopleva, Hartmut Döhner, Anthony Letai, Pierre Fenaux,[...]. N Engl J Med 2020
286
29

Genomic Classification and Prognosis in Acute Myeloid Leukemia.
Elli Papaemmanuil, Moritz Gerstung, Lars Bullinger, Verena I Gaidzik, Peter Paschka, Nicola D Roberts, Nicola E Potter, Michael Heuser, Felicitas Thol, Niccolo Bolli,[...]. N Engl J Med 2016
27

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
Courtney D DiNardo, Keith Pratz, Vinod Pullarkat, Brian A Jonas, Martha Arellano, Pamela S Becker, Olga Frankfurt, Marina Konopleva, Andrew H Wei, Hagop M Kantarjian,[...]. Blood 2019
657
26

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
Gail J Roboz, Courtney D DiNardo, Eytan M Stein, Stéphane de Botton, Alice S Mims, Gabrielle T Prince, Jessica K Altman, Martha L Arellano, Will Donnellan, Harry P Erba,[...]. Blood 2020
97
25

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.
Eytan M Stein, Courtney D DiNardo, Amir T Fathi, Daniel A Pollyea, Richard M Stone, Jessica K Altman, Gail J Roboz, Manish R Patel, Robert Collins, Ian W Flinn,[...]. Blood 2019
146
25

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.
Jorge E Cortes, Florian H Heidel, Andrzej Hellmann, Walter Fiedler, B Douglas Smith, Tadeusz Robak, Pau Montesinos, Daniel A Pollyea, Pierre DesJardins, Oliver Ottmann,[...]. Leukemia 2019
215
22

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.
Hervé Dombret, John F Seymour, Aleksandra Butrym, Agnieszka Wierzbowska, Dominik Selleslag, Jun Ho Jang, Rajat Kumar, James Cavenagh, Andre C Schuh, Anna Candoni,[...]. Blood 2015
585
21

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
Maria E Figueroa, Omar Abdel-Wahab, Chao Lu, Patrick S Ward, Jay Patel, Alan Shih, Yushan Li, Neha Bhagwat, Aparna Vasanthakumar, Hugo F Fernandez,[...]. Cancer Cell 2010
20

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.
Michael D Amatangelo, Lynn Quek, Alan Shih, Eytan M Stein, Mikhail Roshal, Muriel D David, Benoit Marteyn, Noushin Rahnamay Farnoud, Stephane de Botton, Olivier A Bernard,[...]. Blood 2017
187
18

Recurring mutations found by sequencing an acute myeloid leukemia genome.
Elaine R Mardis, Li Ding, David J Dooling, David E Larson, Michael D McLellan, Ken Chen, Daniel C Koboldt, Robert S Fulton, Kim D Delehaunty, Sean D McGrath,[...]. N Engl J Med 2009
18

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.
Hagop M Kantarjian, Xavier G Thomas, Anna Dmoszynska, Agnieszka Wierzbowska, Grzegorz Mazur, Jiri Mayer, Jyh-Pyng Gau, Wen-Chien Chou, Rena Buckstein, Jaroslav Cermak,[...]. J Clin Oncol 2012
698
18

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.
Marina Konopleva, Daniel A Pollyea, Jalaja Potluri, Brenda Chyla, Leah Hogdal, Todd Busman, Evelyn McKeegan, Ahmed Hamed Salem, Ming Zhu, Justin L Ricker,[...]. Cancer Discov 2016
475
17

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Patrick S Ward, Jay Patel, David R Wise, Omar Abdel-Wahab, Bryson D Bennett, Hilary A Coller, Justin R Cross, Valeria R Fantin, Cyrus V Hedvat, Alexander E Perl,[...]. Cancer Cell 2010
16

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
Jeffrey E Lancet, Geoffrey L Uy, Jorge E Cortes, Laura F Newell, Tara L Lin, Ellen K Ritchie, Robert K Stuart, Stephen A Strickland, Donna Hogge, Scott R Solomon,[...]. J Clin Oncol 2018
338
16

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
Andrew H Wei, Pau Montesinos, Vladimir Ivanov, Courtney D DiNardo, Jan Novak, Kamel Laribi, Inho Kim, Don A Stevens, Walter Fiedler, Maria Pagoni,[...]. Blood 2020
131
16

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Lenny Dang, David W White, Stefan Gross, Bryson D Bennett, Mark A Bittinger, Edward M Driggers, Valeria R Fantin, Hyun Gyung Jang, Shengfang Jin, Marie C Keenan,[...]. Nature 2009
15

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
Wei Xu, Hui Yang, Ying Liu, Ying Yang, Ping Wang, Se-Hee Kim, Shinsuke Ito, Chen Yang, Pu Wang, Meng-Tao Xiao,[...]. Cancer Cell 2011
14

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
Andrew H Wei, Stephen A Strickland, Jing-Zhou Hou, Walter Fiedler, Tara L Lin, Roland B Walter, Anoop Enjeti, Ing Soo Tiong, Michael Savona, Sangmin Lee,[...]. J Clin Oncol 2019
272
14

Acute Myeloid Leukemia.
Hartmut Döhner, Daniel J Weisdorf, Clara D Bloomfield. N Engl J Med 2015
14

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.
Katharine Yen, Jeremy Travins, Fang Wang, Muriel D David, Erin Artin, Kimberly Straley, Anil Padyana, Stefan Gross, Byron DeLaBarre, Erica Tobin,[...]. Cancer Discov 2017
190
13

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.
Daniel A Pollyea, Martin S Tallman, Stéphane de Botton, Hagop M Kantarjian, Robert Collins, Anthony S Stein, Mark G Frattini, Qiang Xu, Alessandra Tosolini, Wendy L See,[...]. Leukemia 2019
71
18

IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Chao Lu, Patrick S Ward, Gurpreet S Kapoor, Dan Rohle, Sevin Turcan, Omar Abdel-Wahab, Christopher R Edwards, Raya Khanin, Maria E Figueroa, Ari Melnick,[...]. Nature 2012
12

Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.
Andrew M Intlekofer, Alan H Shih, Bo Wang, Abbas Nazir, Ariën S Rustenburg, Steven K Albanese, Minal Patel, Christopher Famulare, Fabian M Correa, Naofumi Takemoto,[...]. Nature 2018
116
12

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.
Timothy J Ley, Christopher Miller, Li Ding, Benjamin J Raphael, Andrew J Mungall, A Gordon Robertson, Katherine Hoadley, Timothy J Triche, Peter W Laird, Jack D Baty,[...]. N Engl J Med 2013
12

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
Pierre Fenaux, Ghulam J Mufti, Eva Hellstrom-Lindberg, Valeria Santini, Carlo Finelli, Aristoteles Giagounidis, Robert Schoch, Norbert Gattermann, Guillermo Sanz, Alan List,[...]. Lancet Oncol 2009
11

Isocitrate dehydrogenase mutations in myeloid malignancies.
B C Medeiros, A T Fathi, C D DiNardo, D A Pollyea, S M Chan, R Swords. Leukemia 2017
178
11

Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
Mojca Jongen-Lavrencic, Tim Grob, Diana Hanekamp, François G Kavelaars, Adil Al Hinai, Annelieke Zeilemaker, Claudia A J Erpelinck-Verschueren, Patrycja L Gradowska, Rosa Meijer, Jacqueline Cloos,[...]. N Engl J Med 2018
321
11

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML.
Courtney D DiNardo, Farhad Ravandi, Sam Agresta, Marina Konopleva, Koichi Takahashi, Tapan Kadia, Mark Routbort, Keyur P Patel, Mark Brandt, Sherry Pierce,[...]. Am J Hematol 2015
150
11

Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML.
Sung Choe, Hongfang Wang, Courtney D DiNardo, Eytan M Stein, Stéphane de Botton, Gail J Roboz, Jessica K Altman, Alice S Mims, Justin M Watts, Daniel A Pollyea,[...]. Blood Adv 2020
44
25

Age-related clonal hematopoiesis associated with adverse outcomes.
Siddhartha Jaiswal, Pierre Fontanillas, Jason Flannick, Alisa Manning, Peter V Grauman, Brenton G Mar, R Coleman Lindsley, Craig H Mermel, Noel Burtt, Alejandro Chavez,[...]. N Engl J Med 2014
10

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
Pierre Fenaux, Ghulam J Mufti, Eva Hellström-Lindberg, Valeria Santini, Norbert Gattermann, Ulrich Germing, Guillermo Sanz, Alan F List, Steven Gore, John F Seymour,[...]. J Clin Oncol 2010
696
10

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.
Lynn Quek, Muriel D David, Alison Kennedy, Marlen Metzner, Michael Amatangelo, Alan Shih, Bilyana Stoilova, Cyril Quivoron, Maël Heiblig, Christophe Willekens,[...]. Nat Med 2018
79
12

Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia.
Daniel A Pollyea, Brett M Stevens, Courtney L Jones, Amanda Winters, Shanshan Pei, Mohammad Minhajuddin, Angelo D'Alessandro, Rachel Culp-Hill, Kent A Riemondy, Austin E Gillen,[...]. Nat Med 2018
236
10

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.
Jorge E Cortes, Samer Khaled, Giovanni Martinelli, Alexander E Perl, Siddhartha Ganguly, Nigel Russell, Alwin Krämer, Hervé Dombret, Donna Hogge, Brian A Jonas,[...]. Lancet Oncol 2019
133
10

Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN).
Andreas Burchert, Gesine Bug, Lea V Fritz, Jürgen Finke, Matthias Stelljes, Christoph Röllig, Ellen Wollmer, Ralph Wäsch, Martin Bornhäuser, Tobias Berg,[...]. J Clin Oncol 2020
77
12

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
Courtney D DiNardo, Abhishek Maiti, Caitlin R Rausch, Naveen Pemmaraju, Kiran Naqvi, Naval G Daver, Tapan M Kadia, Gautam Borthakur, Maro Ohanian, Yesid Alvarado,[...]. Lancet Haematol 2020
58
17

(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible.
Julie-Aurore Losman, Ryan E Looper, Peppi Koivunen, Sungwoo Lee, Rebekka K Schneider, Christine McMahon, Glenn S Cowley, David E Root, Benjamin L Ebert, William G Kaelin. Science 2013
464
9

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
Gerrit J Schuurhuis, Michael Heuser, Sylvie Freeman, Marie-Christine Béné, Francesco Buccisano, Jacqueline Cloos, David Grimwade, Torsten Haferlach, Robert K Hills, Christopher S Hourigan,[...]. Blood 2018
418
9

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.
Bruce D Cheson, John M Bennett, Kenneth J Kopecky, Thomas Büchner, Cheryl L Willman, Elihu H Estey, Charles A Schiffer, Hartmut Doehner, Martin S Tallman, T Andrew Lister,[...]. J Clin Oncol 2003
9


Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.
Robert K Hills, Sylvie Castaigne, Frederick R Appelbaum, Jacques Delaunay, Stephen Petersdorf, Megan Othus, Elihu H Estey, Hervé Dombret, Sylvie Chevret, Norbert Ifrah,[...]. Lancet Oncol 2014
342
9

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.
Fang Wang, Jeremy Travins, Byron DeLaBarre, Virginie Penard-Lacronique, Stefanie Schalm, Erica Hansen, Kimberly Straley, Andrew Kernytsky, Wei Liu, Camelia Gliser,[...]. Science 2013
542
9

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
Courtney D DiNardo, Keith W Pratz, Anthony Letai, Brian A Jonas, Andrew H Wei, Michael Thirman, Martha Arellano, Mark G Frattini, Hagop Kantarjian, Relja Popovic,[...]. Lancet Oncol 2018
316
9

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing.
Li Ding, Timothy J Ley, David E Larson, Christopher A Miller, Daniel C Koboldt, John S Welch, Julie K Ritchey, Margaret A Young, Tamara Lamprecht, Michael D McLellan,[...]. Nature 2012
8

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
Daniel A Arber, Attilio Orazi, Robert Hasserjian, Jürgen Thiele, Michael J Borowitz, Michelle M Le Beau, Clara D Bloomfield, Mario Cazzola, James W Vardiman. Blood 2016
8

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.
Jay P Patel, Mithat Gönen, Maria E Figueroa, Hugo Fernandez, Zhuoxin Sun, Janis Racevskis, Pieter Van Vlierberghe, Igor Dolgalev, Sabrena Thomas, Olga Aminova,[...]. N Engl J Med 2012
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.